Sign In  |  Register  |  About Santa Clara  |  Contact Us

Santa Clara, CA
September 01, 2020 1:39pm
7-Day Forecast | Traffic

  • Search Hotels in Santa Clara

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Amicus Therapeutics (NQ: FOLD )

9.660 +0.160 (+1.68%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 22, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Amicus Therapeutics

< Previous 1 2 3 Next >
A Closer Look at 8 Analyst Recommendations For Amicus Therapeutics
Via Benzinga
The Analyst Verdict: Amicus Therapeutics In The Eyes Of 8 Experts
Via Benzinga
Amicus Therapeutics Stock: A Deep Dive Into Analyst Perspectives (8 Ratings)
Via Benzinga
Peeling Back The Layers: Exploring Amicus Therapeutics Through Analyst Insights
Via Benzinga
Amicus Therapeutics Settles Patent Lawsuit Teva Pharmaceuticals Over Generic Version Of Its Rare Genetic Disorder Drug
Amicus Therapeutics enters a license agreement with Teva Pharmaceuticals resolving patent litigation over a generic version of Galafold. Teva may market its version starting in 2037, pending FDA... 
Via Benzinga
Topics Intellectual Property Lawsuit
Exposures Financial Intellectual Property Legal
Travelers Posts Upbeat Results, Joins Iridium Communications, Snap-on And Other Big Stocks Moving Higher On Thursday
Via Benzinga
Expert Outlook: Amicus Therapeutics Through The Eyes Of 4 Analysts
Via Benzinga
Evaluating Amicus Therapeutics: Insights From 6 Financial Analysts
Via Benzinga
FOLD Stock Earnings: Amicus Therapeutics Beats EPS, Beats Revenue for Q2 2024
FOLD stock results show that Amicus Therapeutics beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024. 
Via InvestorPlace
This Boston Beer Analyst Turns Bullish; Here Are Top 5 Upgrades For Today.
Via Benzinga
FOLD Stock Earnings: Amicus Therapeutics Beats EPS, Misses Revenue for Q1 2024
FOLD stock results show that Amicus Therapeutics beat analyst estimates for earnings per share but missed on revenue for the first quarter of 2024. 
Via InvestorPlace
Amicus Therapeutics Stock Sees RS Rating Improve To 74
In a welcome move, Amicus Therapeutics stock saw its Relative Strength Rating rise from 69 to 74 on Tuesday. 
Via Investor's Business Daily
Amicus Therapeutics Stock Sees Improved Relative Strength Rating
In a welcome move, Amicus Therapeutics stock saw its Relative Strength Rating rise from 64 to 78 on Friday. 
Via Investor's Business Daily
The Analyst Landscape: 4 Takes On Amicus Therapeutics
Via Benzinga
Amicus Therapeutics: Q1 Earnings Insights
Via Benzinga
The Latest Analyst Ratings for Amicus Therapeutics
Via Benzinga
Earnings Scheduled For March 1, 2023
Companies Reporting Before The Bell • Globalstar (AMEX:GSAT) is expected to report quarterly loss at $0.01 per share on revenue of $38.75 million. 
Via Benzinga
Earnings Preview: Amicus Therapeutics
Via Benzinga
7 Stocks Most Likely to Follow in WeWork’s Woeful Footsteps
These troubled stocks to sell look even worse following WeWork's bankruptcy and will only hurt holders the longer they hold on. 
Via InvestorPlace
Topics Bankruptcy
Exposures Financial Legal
Nike, OPKO Health And Other Big Stocks Moving Higher In Friday's Pre-Market Session
U.S. stock futures traded higher this morning on Friday. Here are some big stocks recording gains in today’s pre-market trading session. 
Via Benzinga
Amicus Therapeutics Drug Scores FDA Approval For Rare Inherited Pompe Disease
The FDA has approved Amicus Therapeutics' (NASDAQ: FOLD) Pombiliti (cipaglucosidase alfa-atga)+Opfolda (miglustat) 65mg capsules for Pompe disease. 
Via Benzinga
Exposures Product Safety
Amicus Therapeutics Stock Reaches 80+ Relative Strength Benchmark
Amicus Therapeutics sees its Relative Strength Rating move into the 80-plus level. 
Via Investor's Business Daily
Amicus Therapeutics Stock Scores Healthy Relative Strength Upgrade
On Thursday, Amicus Therapeutics stock got an upgrade to its Relative Strength (RS) Rating, from 78 to 81. 
Via Investor's Business Daily
FDA Defers Action On Amicus Therapeutics' Much Awaited Pompe Disease Therapy
Via Benzinga
Amicus Therapeutics Stock Sees Improving Market Leadership; Earns 81 RS Rating
On Monday, Amicus Therapeutics stock got an upgrade to its Relative Strength (RS) Rating, to 81, up from 74 a day earlier. 
Via Investor's Business Daily
Amicus Therapeutics Stock Scores Relative Strength Rating Upgrade; Hits Key Benchmark
One key metric to look for in a stock is an 80-plus RS Rating. Amicus Therapeutics stock hit that mark, with a jump from 74 to 82 Friday. 
Via Investor's Business Daily
Fabry Disease Treatment Showdown: Protalix Bio's Elfabrio Joins the Ranks of Sanofi and Amicus Therapeutics
The FDA approved Chiesi Group and Protalix BioTherapeutics Inc's (NASDAQ: PLX) Elfabrio (pegunigalsidase alfa-iwxj) for treating adult  
Via Benzinga
'I Think You Should Take The Money And Run': Cramer On This Stock Up 52% Over Past Month
On CNBC’s "Mad Money Lightning Round," Jim Cramer said Amicus Therapeutics Inc (NASDAQ: FOLD) is an "ideal spec. 
Via Benzinga
Recap: Amicus Therapeutics Q3 Earnings
Amicus Therapeutics (NASDAQ:FOLD) reported its Q3 earnings results on Monday, November 7, 2022 at 06:12 AM. Here's what investors need to know about the announcement. 
Via Benzinga
Provention Bio's Second Try, Apellis's Eye Disorder Drug Review, 3 Adcom Verdicts And More: November's Key PDUFA Catalysts Biotech Investors Must Know
October proved to be a mixed month for the Food and Drug Administration’s regulatory decisions. Two new molecular entities, or NMEs, were approved during the month, bringing the tally for the... 
Via Benzinga
< Previous 1 2 3 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 SantaClara.com & California Media Partners, LLC. All rights reserved.